RLS

Name

RLS

Legal name

RLS (USA) Inc.

Website

https://rls.bio

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Radiopharmacy Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)

akta.pro secondary industries

Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Medical Device & Surgical Kit Courier (Instruments, Implants) (TLAAAIAC), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Radiopharmaceutical distribution
• Nuclear pharmacy services
• PET imaging agents
• SPECT radiopharmaceuticals
• Radiopharmacy network

Headquarters

HQ city

Lake Zurich

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products and Delivery: RLS generates revenue through the manufacture and delivery of radiopharmaceutical unit doses to healthcare facilities. The transaction-based model involves same-day delivery of unit doses to hospitals, imaging centers, and clinics. Revenue is derived from product sales plus associated delivery charges based on distance and fuel costs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

RLS Radiopharmacies is the third-largest nuclear medicine pharmacy network in the United States, operating 29 Joint Commission-accredited radiopharmacy locations across 19 states. The company manufactures, distributes, and delivers unit-dose radiopharmaceuticals (SPECT, PET, and therapeutic agents) to hospitals, imaging centers, and clinics using a vertically integrated supply chain that includes cyclotron production, cGMP manufacturing, and an all-employee courier fleet for same-day delivery.

Product overview

RLS Radiopharmacies operates as a nationwide radiopharmacy network providing a comprehensive portfolio of radiopharmaceuticals through a platform-plus-distribution model. The core offering includes SPECT products (Unit Dosage Technetium products such as Tc99m Sestamibi, Tc99m MDP, Tc99m DTPA, Tc99m MAA), PET radiopharmaceuticals (Gozellix, Illuccix, NETSPOT, Detectnet, Locametz), non-technetium products (Ga-67, I-123, I-131, In-111, Tl-201), cold kits, and Tc99m generators. These are supported by white-glove customized services including ancillary products, hot lab setup, and Health Physics services. RLS distributes Telix products (Gozellix, Illuccix) alongside third-party PET products (NETSPOT/Novartis, Detectnet, Locametz), and also supplies therapeutic products like SIRTeX SIR-Spheres and I-131 compounded therapy capsules.

Differentiator

Problem solved

Functional benefit

Products and services

• Unit Dosage Technetium Products

Quantifiable outcome

• Third-largest nuclear medicine pharmacy network in the U.S.
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

13 partnerships are on record, tiered core, flagship and minor.

• IBAcoreTechnology or IntegrationIBA is a cyclotron supplier for RLS radiopharmacies. RLS operates a network of cyclotrons for producing FDG and other radiopharmaceuticals, with IBA identified as a key equipment supplier partner.
• Telix PharmaceuticalsflagshipStrategic or Co-development PartnerTelix Pharmaceuticals is the parent company of RLS Radiopharmacies. RLS operates as the radiopharmacy distribution network for Telix's portfolio of radiopharmaceutical products, including FDA-approved imaging agents.
• ShowTyme ImagingcoreGTM or Marketing PartnerShowTyme Imaging is a nuclear medicine imaging center that utilizes RLS for daily radiopharmaceutical deliveries. The relationship represents a key customer partnership where RLS serves as the exclusive or primary supplier of FDG and other radiopharmaceuticals.
• ARTMScoreTechnology or IntegrationRLS acquired the ARTMS technology platform, expanding their proprietary manufacturing capabilities for radiopharmaceutical production. This acquisition provides RLS with advanced production technology.
• Cardinal HealthminorChannel Partner/ Reseller/ DistributorCardinal Health was mentioned in connection with NNSA conference participation, indicating a distribution partnership within the nuclear medicine supply chain ecosystem.
• SHINEminorChannel Partner/ Reseller/ DistributorSHINE was mentioned at the NNSA conference in relation to the nuclear medicine supply chain, indicating a partnership within the radiopharmacy supply ecosystem.
• UPPIminorChannel Partner/ Reseller/ DistributorUPPI was mentioned at the NNSA conference, indicating a relationship within the nuclear medicine and radiopharmacy supply chain network.
• VizientcoreGTM or Marketing PartnerVizient is a healthcare improvement company that RLS partners with. RLS participates in Vizient Connections Summit and works with Vizient on healthcare supply chain and procurement relationships.
• PremiercoreGTM or Marketing PartnerPremier is a healthcare improvement company that RLS partners with for healthcare supply chain and procurement optimization.
• NANPcoreStrategic or Co-development PartnerRLS has board member representation at NANP (National Association of Nuclear Pharmacies), indicating a strategic partnership in industry advocacy and standards development.
• SNMMIcoreStrategic or Co-development PartnerSNMMI (Society of Nuclear Medicine and Molecular Imaging) is a professional organization that RLS participates in, supporting industry standards, education, and professional development in nuclear medicine.
• ASNCcoreStrategic or Co-development PartnerASNC (American Society of Nuclear Cardiology) is a professional organization that RLS participates in for industry standards and professional collaboration in nuclear cardiology.
• NMEUminorGTM or Marketing PartnerNMEU (Nuclear Medicine Executive University) is an affiliate member organization in the nuclear medicine industry that RLS participates in for executive education and industry networking.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• PETNET Solutions (Siemens Healthineers): PETNET Solutions, a Siemens Healthineers subsidiary, operates a network of cyclotron-equipped radiopharmacies producing and distributing PET imaging agents (notably FDG). It serves hospitals and imaging centers in overlapping U.S. geographies and competes directly with RLS in cyclotron-based PET tracer distribution.
• Curium Pharma: Curium Pharma manufactures and distributes radiopharmaceuticals, including SPECT and PET imaging agents, across the U.S. and Europe. Its vertically integrated model, from Mo-99 production through unit-dose distribution to hospitals, makes it a direct peer to RLS in radiopharmaceutical supply.
• PharmaLogic: PharmaLogic operates a network of radiopharmacies and contract manufacturing sites producing and distributing unit-dose radiopharmaceuticals. Its cGMP-compliant, multi-site radiopharmacy network directly overlaps with RLS in serving hospitals, imaging centers, and clinics.
• SOFIE Biosciences: SOFIE Biosciences (formerly IBA Molecular NA) operates a network of radiopharmacies and PET tracer manufacturing facilities across the United States. It produces and distributes FDG and other PET radiopharmaceuticals to hospitals and imaging centers, competing directly with RLS in PET tracer supply and theranostic manufacturing.
• Cardinal Health Nuclear Pharmacy Services: Cardinal Health Nuclear Pharmacy Services (formerly Syncor) is the largest U.S. radiopharmacy network. It distributes unit-dose radiopharmaceuticals to hospitals and imaging centers nationwide with a directly overlapping product portfolio (Tc-99m, PET tracers, I-131, Ga-68), making it RLS's primary direct competitor.
• Jubilant Radiopharma: Jubilant Radiopharma (formerly Triad Isotopes) is the second-largest nuclear medicine pharmacy network in the United States. It operates a comparable radiopharmacy distribution model with cyclotron-based production and same-day unit dose delivery to hospitals and imaging centers, making it RLS's closest head-to-head competitor.

Broad incumbents

• Lantheus Holdings: Lantheus Holdings is a leading radiopharmaceutical manufacturer (e.g., Pylarify PSMA-PET, Definity) that relies on third-party radiopharmacy networks for unit-dose distribution. It is comparable to RLS as an adjacent player in the radiopharmaceutical value chain, with overlapping customers and products.
• GE Healthcare: GE Healthcare is a broad incumbent in medical imaging and radiopharmaceuticals, including its own PET tracer production historically and significant installed base of imaging equipment. While its scale extends well beyond radiopharmacy, it competes with RLS as both an upstream imaging modality vendor and adjacent radiopharma producer.

Others

• Telix Pharmaceuticals: Telix Pharmaceuticals is the parent company of RLS Radiopharmacies and a global theranostics developer (Illuccix, Gozellix). It is comparable as both RLS's strategic owner and the upstream supplier of proprietary products distributed through RLS's nationwide radiopharmacy network.

Emerging players

• Ionetix: Ionetix operates cyclotron-based production for PET tracers and theranostic isotopes (e.g., Ga-68, Cu-64) with a smaller footprint than RLS. Its cyclotron and isotope supply capabilities overlap with RLS's vertical integration strategy in PET and theranostics.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rlsgroup

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RLS